



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/608,886	06/26/2003	Todd Hembrough	05213-3041 (13663.105099)	7823
20786	7590	06/26/2007	EXAMINER HEARD, THOMAS SWEENEY	
KING & SPALDING LLP 1180 PEACHTREE STREET ATLANTA, GA 30309-3521			ART UNIT	PAPER NUMBER 1654
		MAIL DATE 06/26/2007	DELIVERY MODE PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/608,886	HEMBROUGH ET AL.	
	Examiner	Art Unit	
	Thomas S. Heard	1654	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 18 May 2007.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-20 is/are pending in the application.
- 4a) Of the above claim(s) 1,2,4 and 6-20 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 3 and 5 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date 6/4/2007
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____
- 5) Notice of Informal Patent Application
 6) Other: _____

DETAILED ACTION

The Applicants Amendments to the claims received on 5/18/2007 is acknowledged. The text of those sections of Title 35 U.S. Code not included in the action can be found in the prior office action. Rejections or objections not addressed in this office action with respect to the previous office action mailed 11/15/2006 are hereby withdrawn.

Claim(s) 1-20 are pending. Applicants have elected the species, SEQ ID NO:1, readable upon claims 3 and 5. Claims 1, 2, 4, and 6-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected subject, there being no allowable generic or linking claim. Applicants claim statutes identifier does not properly reflect the current status of the claims. Correction is required in the next submission of claims.. No amendments to the claims have been made. Claims 3 and 5 are hereby examined on the merits.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 3 stands rejected under 35 U.S.C. 112, first paragraph, as containing subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor, at the time the application was filed, had possession of the claimed invention.

Applicant's arguments have been carefully considered but are not found persuasive. Applicants are arguing enablement, but the rejection is a 112 First Paragraph Written Description. Therefore, the arguments are not pertinent to the rejection and the rejection is maintained.

The Written Description Guidelines for examination of patent applications indicates, "the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical characteristics and/or other chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show applicant was in possession of the claimed genus." (see MPEP 2164).

In the instant case the claims encompass a number of discreet sequences of amino acids. The specification discloses a number of sequences with their retro inverse sequences, in addition to sequences with non-natural amino acids indicating a number of distinct sub-genus of molecules embraced by the claims. However, as discussed above, the claims encompass any active fragment. Applicants have not described what an active fragment is. The active fragment could be an amino acid or a proton. The peptides do not share a common core structure, such as SEQ ID NO:1 or ENMD, a non-peptide molecule. Conception does not occur unless one has a mental picture of the structure of the molecule, or is able to define it by its method of preparation, its physical or chemical properties, or whatever characteristics sufficiently distinguish it.

Thus, a fragment from one of these molecules is not correlated to its function. Further, it is not sufficient to define it solely by its principle property, e.g., active fragment, for generating SCCE-specific T cells, because an alleged conception having no more specificity than that is simply a wish to know the identity of any material with that biological property.

Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the *invention*. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed*." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See *Vas-Cath* at page 1116). As discussed above, the skilled artisan cannot envision the detailed chemical structure of the encompassed genus of SCCE proteins and fragments thereof, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes v. Baird*, claims directed to mammalian FGF's were found to be unpatentable due to lack of written description for that broad class. The specification provided only for a number of specific peptides. Therefore, only the peptides disclosed in the specification but not the full breadth of the claim active fragments) meets the written description provision of 35 U.S.C. §112, first paragraph. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision.

Because Applicants have not provided written description of active fragments of the protein, peptides, biomolecule of the claims SEQ ID NOS, and that an active fragment from a molecule that comprises any of the sequences of Claim 3 does not have to come from the defined sequences. Accordingly, it is deemed that the specification fails to provide adequate written description for the genus of the claims and does not

reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the entire scope of the claimed invention.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 3 and 5 stand rejected under 35 U.S.C. 102(e) as being anticipated by Selberg et al, US 2003/0138388. Selberg et al discloses the peptide LIGK SEQ ID NO:3 (SEQ ID NO:1 instantly claimed), see [0031] on page 2.

Applicants arguments have been carefully considered but are not deemed persuasive. Applicants have argued:

According to the Examiner, Claims 3 and 5 are rejected under 35 U.S.C §102(e) as being anticipated by Selberg et al. US 2003/0138388. The Examiner states that Selberg et al. disclose the peptide LIGK SEQ ID NO:3 (SEQ ID NO: 1 instantly claimed), see [0031] on page 2. Applicants respectfully submit that the Selberg et al. is specifically limited to the use of the disclosed compositions for purposes of increased pigment production and deposition *in vivo*. According to Selberg et al. US 2003/0138388 the compositions are provided in various embodiments for darkening the skin, mainly for cosmetic purposes. In contrast, the presently claimed compositions are defined and claimed in accordance with their ability for inhibiting proteinase activated receptor activity comprising a protein, peptide, biomolecule or active fragment thereof.

Applicants are claiming a composition. What the composition's intended use is for is not given patentable weight, barring enablement rejections that might be made.

Applicants are claiming a composition of SEQ ID NO:1 and Selberg et al discloses such a peptide. Despite Selberg's intended use, the Applicant's elected species is anticipated by the prior art. Therefore, the compound of SEQ ID NO:1 is anticipated by the prior art.

Conclusion

No Claims are allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.


Art Unit: 1654

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thomas S. Heard whose telephone number is (571) 272-2064. The examiner can normally be reached on 9:00 a.m. to 6:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on (571) 272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

TSH



ANISH GUPTA
PRIMARY EXAMINER